Xiaobo Cao

1.0k total citations
27 papers, 861 citations indexed

About

Xiaobo Cao is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Biotechnology. According to data from OpenAlex, Xiaobo Cao has authored 27 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Biotechnology. Recurrent topics in Xiaobo Cao's work include Occupational and environmental lung diseases (12 papers), Cell death mechanisms and regulation (11 papers) and Cancer Research and Treatments (8 papers). Xiaobo Cao is often cited by papers focused on Occupational and environmental lung diseases (12 papers), Cell death mechanisms and regulation (11 papers) and Cancer Research and Treatments (8 papers). Xiaobo Cao collaborates with scholars based in United States and China. Xiaobo Cao's co-authors include W. Roy Smythe, W. Roy Smythe, Lidong Zhang, David J. McConkey, James Littlejohn, Ferah Ece, Bingliang Fang, Daniel C. Jupiter, Steven Fletcher and Jeremy L. Yap and has published in prestigious journals such as Cancer Research, ACS Applied Materials & Interfaces and American Journal Of Pathology.

In The Last Decade

Xiaobo Cao

25 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaobo Cao United States 18 554 241 215 115 97 27 861
W. Roy Smythe United States 13 351 0.6× 145 0.6× 136 0.6× 83 0.7× 34 0.4× 21 567
Sanchita Rauth United States 18 558 1.0× 118 0.5× 378 1.8× 42 0.4× 171 1.8× 36 962
Akiko Tohgo Japan 18 501 0.9× 83 0.3× 526 2.4× 45 0.4× 86 0.9× 37 930
Atsushi Miwa Japan 14 438 0.8× 100 0.4× 255 1.2× 34 0.3× 36 0.4× 33 734
Yun Hee Kang South Korea 18 535 1.0× 115 0.5× 332 1.5× 43 0.4× 258 2.7× 44 1.0k
Yansu Chen China 20 664 1.2× 120 0.5× 349 1.6× 29 0.3× 124 1.3× 39 1.0k
Hubert E. Appert United States 16 485 0.9× 87 0.4× 345 1.6× 65 0.6× 104 1.1× 41 962
Navneet Momi United States 13 522 0.9× 50 0.2× 408 1.9× 44 0.4× 141 1.5× 19 854
Dongkyoo Park United States 14 545 1.0× 90 0.4× 287 1.3× 20 0.2× 93 1.0× 19 802

Countries citing papers authored by Xiaobo Cao

Since Specialization
Citations

This map shows the geographic impact of Xiaobo Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobo Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobo Cao more than expected).

Fields of papers citing papers by Xiaobo Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobo Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobo Cao. The network helps show where Xiaobo Cao may publish in the future.

Co-authorship network of co-authors of Xiaobo Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobo Cao. A scholar is included among the top collaborators of Xiaobo Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobo Cao. Xiaobo Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meraz, Ismail M., Mourad Majidi, Xiaobo Cao, et al.. (2018). TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras -Mutant Mouse Lung Cancer Models. Cancer Immunology Research. 6(2). 163–177. 42 indexed citations
2.
Gentile, Emanuela, Taro Oba, Jing Lin, et al.. (2017). Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget. 8(29). 48222–48239. 6 indexed citations
3.
4.
Jupiter, Daniel C., et al.. (2012). Molecular pathogenesis of malignant mesothelioma. Expert Reviews in Molecular Medicine. 14. e12–e12. 32 indexed citations
5.
Jupiter, Daniel C., Steven Fletcher, Jeremy L. Yap, et al.. (2012). The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer. 12(1). 541–541. 70 indexed citations
6.
Yap, Jeremy L., Xiaobo Cao, Kenno Vanommeslaeghe, et al.. (2012). Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors. Organic & Biomolecular Chemistry. 10(15). 2928–2928. 54 indexed citations
7.
Zhang, Lidong, et al.. (2010). Characterization of bortezomib-adapted I-45 mesothelioma cells. Molecular Cancer. 9(1). 110–110. 28 indexed citations
8.
Cao, Xiaobo, James Littlejohn, Lidong Zhang, et al.. (2009). Up-Regulation of Bcl-xl by Hepatocyte Growth Factor in Human Mesothelioma Cells Involves ETS Transcription Factors. American Journal Of Pathology. 175(5). 2207–2216. 17 indexed citations
9.
Littlejohn, James, et al.. (2008). Bcl‐xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. International Journal of Cancer. 123(1). 202–208. 23 indexed citations
10.
Childs, Ed W., Binu Tharakan, Felicia A. Hunter, John H. Tinsley, & Xiaobo Cao. (2007). Apoptotic signaling induces hyperpermeability following hemorrhagic shock. American Journal of Physiology-Heart and Circulatory Physiology. 292(6). H3179–H3189. 69 indexed citations
11.
Cao, Xiaobo, et al.. (2007). Bcl2/bcl-xl inhibitor engenders apoptosis and increases chemo-sensitivity in mesothelioma. Cancer Biology & Therapy. 6(2). 246–252. 29 indexed citations
12.
Cao, Xiaobo, et al.. (2005). Down-regulation of bcl-xl gene expression with histone deacetylase inhibitor. Cancer Research. 65. 1270–1270. 1 indexed citations
13.
Cao, Xiaobo, et al.. (2005). Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. Journal of Thoracic and Cardiovascular Surgery. 130(2). 393–400. 15 indexed citations
14.
Zhu, Hongbo, Lidong Zhang, Jason J. Davis, et al.. (2005). Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA. Cancer Biology & Therapy. 4(4). 399–403. 48 indexed citations
15.
Miller, S. D., et al.. (2004). Gene therapy for sarcoma utilizing adenoviral transfer of the β-glucuronidase and bax genes and an anthracyline prodrug. Journal of Surgical Research. 121(2). 153–158. 2 indexed citations
16.
Mohiuddin, Imran, et al.. (2002). Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Annals of Surgical Oncology. 9(3). 310–316. 21 indexed citations
17.
Smythe, W. Roy, et al.. (2002). Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. Journal of Thoracic and Cardiovascular Surgery. 123(6). 1191–1198. 41 indexed citations
18.
Cao, Xiaobo, Sunil Chada, Abner M. Mhashilkar, et al.. (2002). Adenoviral Transfer of mda-7 Leads to BAX Up-regulation and Apoptosis in Mesothelioma Cells, and is Abrogated by Over-expression of BCL-XL. Molecular Medicine. 8(12). 869–876. 35 indexed citations
19.
Cao, Xiaobo, et al.. (2001). Histone Deacetylase Inhibitor Downregulation of bcl-xl Gene Expression Leads to Apoptotic Cell Death in Mesothelioma. American Journal of Respiratory Cell and Molecular Biology. 25(5). 562–568. 103 indexed citations
20.
Mohiuddin, Imran, Xiaobo Cao, Bingliang Fang, Masahiko Nishizaki, & W. Roy Smythe. (2001). Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Therapy. 8(8). 547–554. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Roy Smythe Breakdown of academic impact, for papers by Sanchita Rauth Breakdown of academic impact, for papers by Akiko Tohgo Breakdown of academic impact, for papers by Atsushi Miwa Breakdown of academic impact, for papers by Yun Hee Kang Breakdown of academic impact, for papers by Yansu Chen Breakdown of academic impact, for papers by Hubert E. Appert Breakdown of academic impact, for papers by Navneet Momi Breakdown of academic impact, for papers by Dongkyoo Park
Rankless by CCL
2026